Evaluation of the sedative properties of PK 8165 (pipequaline), a benzodiazepine partial agonist, in normal subjects.

abstract：:Fourteen cases of depression resistant to multiple treatments were treated by lithium augmentation of fluoxetine. Tolerability of the treatment was poor. Lithium and fluoxetine may be a possible treatment for resistant depression but there is caution regarding tolerability and toxicity with the relatively high doses o...

journal_title：International clinical psychopharmacology

authors： Hawley CJ,Roberts AG,Baldwin DS

更新日期：1994-04-01 00:00:00

abstract：:It has been suggested that dopamine/serotonin (5-HT) imbalance, with relative enhancement of serotonergic activity, might be one of the possible pathophysiological mechanisms underlying neuroleptic-induced akathisia. On the basis of preclinical data, which imply that the partial 5-HT1A agonist buspirone possesses anti...

journal_title：International clinical psychopharmacology

authors： Poyurovsky M,Weizman A

更新日期：1997-09-01 00:00:00

abstract：:Premenstrual dysphoria (PMD) is a severe form of premenstrual syndrome, afflicting approximately 5% of all women of fertile age. The cardinal symptoms are irritability and anger. In addition, sadness, tension and carbohydrate craving are common complaints. The symptoms surface regularly between ovulation and menstruat...

journal_title：International clinical psychopharmacology

authors： Eriksson E

更新日期：1999-05-01 00:00:00

abstract：:This case series describes the development of retrograde ejaculation with the antipsychotic iloperidone. Iloperidone is a relatively new antipsychotic and has a strong α-1 receptor antagonism, which may explain this rare adverse effect. ...

journal_title：International clinical psychopharmacology

authors： Freeman SA

更新日期：2013-05-01 00:00:00

abstract：:A number of compounds having an effect on serotonergic transmission have been shown to have a beneficial therapeutic action in patients with bulimia nervosa. Many previous studies, however, have suffered from methodological shortcomings, in particular small population sizes. This article reviews present data which sug...

journal_title：International clinical psychopharmacology

authors： Wood A

更新日期：1993-01-01 00:00:00

abstract：:The utility of milnacipran in the treatment of major depression has been the subject of an extensive clinical development programme. Comparative studies with tricyclic antidepressant drugs have demonstrated equivalent efficacy, with improved tolerability, in particular with respect to autonomic effects. In comparison ...

journal_title：International clinical psychopharmacology

authors： Bisserbe JC

更新日期：2002-06-01 00:00:00

abstract：:The therapeutic concentrations of antipsychotic drugs in the patient's plasma water or spinal fluid are identical to their blocking potencies in vitro at the dopamine D2 receptor, with the exception of clozapine which acts at D4. The variation in K values between laboratories stems from the fact that the apparent K va...

journal_title：International clinical psychopharmacology

authors： Seeman P

更新日期：1995-09-01 00:00:00

abstract：:Methylamphetamine given intravenously as a single 15 mg dose led to a pronounced elevation of mood in 7 out of 21 depressed patients compared to a control injection of sterile water administered on another occasion in random order under double-blind conditions. All 7 responders experienced an increase of VAS self-rati...

journal_title：International clinical psychopharmacology

authors： Cookson J,Silverstone T

更新日期：1986-04-01 00:00:00

abstract：:Long-term treatment with benzodiazepines (BZD) should be avoided in dementia patients because of an increased risk of adverse events. We evaluated how continuously dementia patients were prescribed BZD over 12 months. For this observational study, we used claims data from a large German public sickness fund for 2014 a...

journal_title：International clinical psychopharmacology

authors： Hessmann P,Jan Zeidler,Neubauer S,Abdel-Hamid M,Stahmeyer J,Eberhard S,Wolff-Menzler C,Wiltfang J,Kis B

更新日期：2018-09-01 00:00:00

abstract：:The DIABCARE Q-Net project developed a complete and integrated information technology system to monitor diabetes care, according to the gold standards of the St Vincent Declaration Action Program. This is the first Telematic platform for standardized documentation on medical quality and evaluation across Europe, which...

journal_title：International clinical psychopharmacology

authors： Piwernetz K

更新日期：2001-04-01 00:00:00

abstract：:The objective of this study was to assess the response of anxiety and depression symptoms to methylphenidate (MPH) treatment in patients with Asperger syndrome (AS) combined with attention deficit/hyperactivity disorder (ADHD). A group of 12 patients with AS/ADHD, aged 8-18 years, received 12 weeks of MPH treatment. T...

journal_title：International clinical psychopharmacology

authors： Golubchik P,Rapaport M,Weizman A

更新日期：2017-09-01 00:00:00

abstract：:The purpose of this study was to compare the efficacy and safety of risperidone and haloperidol in treatment-resistant chronic schizophrenic patients. Subjects (n = 78) who met DSM-III criteria for schizophrenia were randomly assigned to receive 6 mg/day of risperidone or 20 mg/day of haloperidol for 12 weeks. Clinica...

journal_title：International clinical psychopharmacology

authors： Zhang XY,Zhou DF,Cao LY,Zhang PY,Wu GY,Shen YC

更新日期：2001-11-01 00:00:00

abstract：:Body dysmorphic disorder (BDD) is a relatively common and impairing disorder. Selective serotonin reuptake inhibitors (SRIs) appear selectively efficacious for BDD, but pharmacotherapy research is limited, and escitalopram has not been studied. Fifteen subjects with BDD were treated with escitalopram and assessed with...

journal_title：International clinical psychopharmacology

authors： Phillips KA

更新日期：2006-05-01 00:00:00

abstract：:Out of ten consecutive patients with DSM-III-R obsessive-compulsive disorder without any previous history of bipolarity, three patients showed antidepressant-induced hypomania (clomipramine, one patient; fluvoxamine, two patients) within the first 5 to 8 weeks of the drug treatment. These data support the previous res...

journal_title：International clinical psychopharmacology

authors： Rihmer Z,Barsi J,Belsõ N,Pestality P,György S

更新日期：1996-09-01 00:00:00

abstract：:The pattern of brain metabolic changes produced by olanzapine has yet to be described, despite the theoretical and clinical interest of this new antipsychotic. We studied a group of 17 schizophrenic patients who underwent two fluoro-deoxyglucose-positron emission tomography (FDG-PET) studies under two different condit...

journal_title：International clinical psychopharmacology

authors： Molina V,Gispert JD,Reig S,Pascau J,Martínez R,Sanz J,Palomo T,Desco M

更新日期：2005-01-01 00:00:00

abstract：:Systematic information about Latino clozapine users is still scarce. Our aim was to evaluate the risk of clozapine-associated neutropenia in a Chilean cohort using the last Food and Drug Administration's recommendations for clozapine monitoring. Findings should improve clinical practice and promote changes in clozapin...

journal_title：International clinical psychopharmacology

authors： Mena CI,Nachar RA,Crossley NA,González-Valderrama AA

更新日期：2019-09-01 00:00:00

abstract：:The chronic course of major depressive disorder (MDD) often impedes the ability of patients to achieve full remission. Return of full functioning is a critical goal of antidepressant pharmacotherapy as the presence of residual depressive symptoms is associated with an increased risk of relapse. Treatment guidelines re...

journal_title：International clinical psychopharmacology

authors： Carrasco JL,Kornstein SG,McIntyre RS,Fayyad R,Prieto R,Salas M,Mackell J,Boucher M

更新日期：2016-05-01 00:00:00

abstract：:The interaction between plasma concentrations of the tricyclic antidepressant amitriptyline and the metabolism of the new antipsychotic risperidone was studied in 12 patients with chronic schizophrenia. Each patient received 3 mg risperidone twice a day for 28 days. Amitriptyline was coadministered at doses of 50 mg/d...

journal_title：International clinical psychopharmacology

authors： Sommers DK,Snyman JR,van Wyk M,Blom MW,Huang ML,Levron JC

更新日期：1997-05-01 00:00:00

abstract：:Serotonin is a key neurotransmitter in the central nervous system. In recent years its role in the pathophysiology and pharmacology of depression has been extensively investigated. Neuroendocrine studies suggest decreased serotonergic responsivity in patients with major depression. The fact that the majority of patien...

journal_title：International clinical psychopharmacology

authors： Dinan TG

更新日期：1996-03-01 00:00:00

abstract：:One of the most effective treatments for children with Attention Deficit Disorder with Hyperactivity (ADDH) has been the prescription of methylphenidate (MPH). While laboratory-based evidence indicates that MPH effects may be rate-dependent, little is known about changes evinced in operant behavior controlled by compl...

journal_title：International clinical psychopharmacology

authors： DuPaul GJ,Rapport MD,Vyse SA

更新日期：1988-10-01 00:00:00

abstract：:Negative symptoms are a key feature of schizophrenia. Novel (atypical) antipsychotic drugs, unlike conventional antipsychotics, cause substantial reductions in Positive and Negative Symptom Scale (PANSS) scores. Negative symptoms, however, can arise from both the pathology of the disease (primary negative symptoms) an...

journal_title：International clinical psychopharmacology

authors： Möller HJ

更新日期：1998-03-01 00:00:00

abstract：:Treatments given to patients with primary psychotic disorders include mood stabilizers (MSs) combined with other psychotropics, despite the limited evidence of efficacy, safety, and lack of regulatory approval. We analyzed records of 636 inpatients at the McLean Hospital (2002-2009), who were diagnosed with bipolar di...

journal_title：International clinical psychopharmacology

authors： Ventriglio A,Vincenti A,Centorrino F,Talamo A,Fitzmaurice G,Baldessarini RJ

更新日期：2011-03-01 00:00:00

abstract：:The clinical trial programme of sertraline, a selective serotonin re-uptake inhibitor, has shown the drug to have a favourable safety and toleration profile. In contrast, the tricyclic antidepressant, amitriptyline, produced a significant level of side effects, particularly anticholinergic. The side-effect profile of ...

journal_title：International clinical psychopharmacology

authors： Doogan DP

更新日期：1991-12-01 00:00:00

abstract：:In a sample of 2096 consecutive primary care patients recruited in the Paris region, social phobia was a highly prevalent disorder (5.1%). The most frequent comorbid condition was depressive episode, which affected 70% of patients with social phobia of early onset (at less than 15 years of age), while the highest asso...

journal_title：International clinical psychopharmacology

authors： Lecrubier Y,Weiller E

更新日期：1997-10-01 00:00:00

abstract：:The side effects of antipsychotic drugs have always been a major concern for clinicians and the appreciation of their importance in the treatment of schizophrenia has increased steadily over the years. Epidemiological studies as well as trials of the prevention and treatment of antipsychotic side effects are the conse...

journal_title：International clinical psychopharmacology

authors： Whitworth AB,Fleischhacker WW

更新日期：1995-01-01 00:00:00

abstract：:Neuroleptics are of established efficacy in mania. Controlled data on the use of olanzapine in mania is however, absent. In this study, 30 patients meeting DSM-IV criteria for mania were randomly allocated to receive either olanzapine or lithium in a 4 week double-blind randomized controlled design. There were no sign...

journal_title：International clinical psychopharmacology

authors： Berk M,Ichim L,Brook S

更新日期：1999-11-01 00:00:00

abstract：:The aim of this study was to evaluate flexibly dosed brexpiprazole for early-episode schizophrenia through the assessment of efficacy, social functioning, and tolerability. This was an exploratory, 16-week, open-label, flexible-dose (1, 2, 3, or 4 mg/day; target dose 3 mg/day) study in outpatients with early-episode s...

journal_title：International clinical psychopharmacology

authors： Malla A,Ota A,Nagamizu K,Perry P,Weiller E,Baker RA

更新日期：2016-11-01 00:00:00

abstract：:Amisulpride is a novel antipsychotic with a pharmacological and clinical profile that differs from that of other atypical agents. Amisulpride is highly selective for dopamine D2/D3 receptor subtypes located in the limbic region, which is highly predictive of potent antipsychotic activity with a low potential to cause ...

journal_title：International clinical psychopharmacology

authors： Lecrubier Y

更新日期：2000-12-01 00:00:00

abstract：:The use of certain atypical antipsychotics has been associated with metabolic disturbances. We have assessed the evolution of body weight and glycaemia during a 6-month randomized comparative trial of amisulpride and olanzapine. Three hundred and seventy-seven adult patients with schizophrenia were randomized to eithe...

journal_title：International clinical psychopharmacology

authors： Peuskens J,De Hert M,Mortimer A,SOLIANOL Study Group.

更新日期：2007-05-01 00:00:00

abstract：:Good evidence now exists for a therapeutic action of carbamazepine (CBZ) both in acute mania and in the prophylaxis of manic depression. Comparison with other existing therapies and incidence of adverse effects in psychiatric patients also deserve more clinical research. This paper reviews these clinical issues and th...

journal_title：International clinical psychopharmacology

authors： Elphick M

更新日期：1988-07-01 00:00:00